Vaccine Therapy in Treating Patients With Stage I, Stage II, or Stage III Non-small Cell Lung Cancer

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborator:
Information provided by (Responsible Party):
University of Kentucky
ClinicalTrials.gov Identifier:
NCT00103116
First received: February 7, 2005
Last updated: February 21, 2013
Last verified: February 2013

February 7, 2005
February 21, 2013
October 2004
April 2008   (final data collection date for primary outcome measure)
Immunologic response [ Time Frame: July/2005-Oct/2007 ] [ Designated as safety issue: No ]
Measurement of antigen specific reaction through six months post-vaccine
Not Provided
Complete list of historical versions of study NCT00103116 on ClinicalTrials.gov Archive Site
Comparison of clinical outcomes to historical controls [ Time Frame: July/2005-May/2012 ] [ Designated as safety issue: No ]
Documentation of radiographic surveillance for recurrence or progression for 5 years post-vaccine
Not Provided
Not Provided
Not Provided
 
Vaccine Therapy in Treating Patients With Stage I, Stage II, or Stage III Non-small Cell Lung Cancer
Autologous Dendritic Cell Vaccines in Non-small Cell Lung Cancer (NSCLC)

RATIONALE: Vaccines made from a person's white blood cells and allogeneic tumor cells may make the body build an effective immune response to kill tumor cells.

PURPOSE: This phase II trial is studying how well vaccine therapy works in treating patients with stage I, stage II, or stage III non-small cell lung cancer.

OBJECTIVES:

  • Determine the immunologic effects of adjuvant vaccine therapy comprising autologous dendritic cells loaded with allogeneic non-small cell lung cancer (NSCLC) cells in patients with unresectable stage IIIA or IIIB, or resected stage I-IIIB NSCLC.
  • Determine the potential clinical efficacy of this vaccine in these patients.

OUTLINE: This is an open-label study. Patients are stratified according to type of prior primary therapy (surgical vs nonsurgical).

Patients undergo leukapheresis over 3-4 hours to harvest mononuclear cells for the production of dendritic cells (DC). DC are then pulsed with allogeneic non-small cell lung cancer cells to produce an autologous dendritic cell vaccine. Patients receive vaccine intradermally once a month for 2 months in the absence of disease recurrence or unacceptable toxicity.

Patients are followed monthly for 4 months, every 6 months for 2 years, and then periodically thereafter.

PROJECTED ACCRUAL: A total of 60 patients (30 per stratum) will be accrued for this study within 3 years.

Interventional
Phase 2
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Lung Cancer
Biological: therapeutic autologous dendritic cells

Dendritic cells made from white blood cells obtained through out-patient leukapheresis procedure.

Vaccine given by injection under the skin in the front, upper thigh. Two vaccine injections total, given one month a part.

Experimental: Vaccine
Intervention: Biological: therapeutic autologous dendritic cells
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
60
Not Provided
April 2008   (final data collection date for primary outcome measure)

DISEASE CHARACTERISTICS:

  • Histologically confirmed non-small cell lung cancer (NSCLC)

    • Meets 1 of the following stage criteria:

      • Completely resected stage I-IIIB disease

        • Underwent surgical resection > 4 weeks but ≤ 4 years ago
      • Unresectable stage IIIA or IIIB disease AND previously treated with definitive radiotherapy or chemotherapy > 6 weeks ago
    • Bronchoalveolar carcinomas allowed
  • Clinically stable disease by chest x-ray or CT scan within the past 6 weeks

    • No progressive disease
  • No malignant pleural or pericardial effusions

PATIENT CHARACTERISTICS:

Age

  • 18 to 80

Performance status

  • ECOG 0-1

Life expectancy

  • Not specified

Hematopoietic

  • Hemoglobin ≥ 9.0 g/dL

Hepatic

  • Bilirubin ≤ 2.5 times upper limit of normal (ULN)
  • AST and ALT ≤ 2.5 times ULN
  • No known history of infectious hepatitis

Renal

  • Creatinine ≤ 3 mg/dL
  • Ionized calcium ≥ 0.9 mmol/L (may be replaced)

Cardiovascular

  • No known New York Heart Association class III-IV congestive heart failure
  • No hemodynamically significant valvular heart disease
  • No myocardial infarction within the past 6 months
  • No active angina pectoris
  • No uncontrolled ventricular arrhythmia
  • No stroke within the past year
  • No known cerebrovascular disease
  • No other significant cardiac disease by echocardiogram, stress test, or risk assessment by cardiologist (for patients suspected of cardiac disease by history or physical exam)

Immunologic

  • No known HIV positivity
  • No other immunosuppressive disorders, including chronic disorders

Other

  • Not pregnant
  • Negative pregnancy test
  • Potassium ≥ 3.0 mEq/L (may be replaced)
  • Able to tolerate modest blood volume and electrolyte shifts during leukapheresis
  • No other malignancy

PRIOR CONCURRENT THERAPY:

Biologic therapy

  • Prior biologic therapy allowed
  • Other concurrent biologic therapy allowed

Chemotherapy

  • See Disease Characteristics
  • No concurrent chemotherapy

Endocrine therapy

  • No concurrent steroids during and for 16 weeks after study treatment

Radiotherapy

  • See Disease Characteristics
  • No concurrent radiotherapy

Surgery

  • See Disease Characteristics

Other

  • Prior neoadjuvant or adjuvant therapy for surgically resected patients allowed
  • No concurrent shorter courses of immunosuppressive medications during and for 16 weeks after study treatment
  • No concurrent chronic immunosuppressive medications
  • Concurrent cyclooxygenase-2 inhibitors allowed
Both
18 Years to 80 Years
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00103116
CDR0000410830, R21CA091624, UKMC-IRB-0391-F2R, UKMC-CTRF-G-01-009
Not Provided
University of Kentucky
University of Kentucky
National Cancer Institute (NCI)
Study Chair: Edward Hirschowitz, MD Lucille P. Markey Cancer Center at University of Kentucky
University of Kentucky
February 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP